About AngioTox

AngioTox is an EU FP7-funded IAPP project integrating expertise in biomarker discovery, histopathology, multi-modality in vivo imaging and automated image analysis. 

The AngioTox Consortium was established in 2010 to mechanistically assess the toxicities associated with the use of angiogenesis inhibitors for the treatment of cancer. The ultimate goal of this consortium is to identify an AngioTox Safety Panel of toxicologic markers to facilitate improved screening of angiogenesis inhibitor toxicologic parameters, inform clinical drug dosing regimens, facilitate the development of more specific and potent angiogenesis inhibitors and significantly improve patient care.